A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).

Katherine Fuh,Thomas J. Herzog,Kathleen N. Moore,Tashanna K.N. Myers,Bobbie J. Rimel,Joyce F. Liu,Angeles Alvarez Secord,Erika Hamilton,Thomas J. Reid,Sharyn N. Lewin,Mary M. Mullen,K.A. Mills,Randy Anderson,Reshma A. Rangwala

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).

2021

Katherine Fuh
Thomas J. Herzog
Kathleen N. Moore
Tashanna K.N. Myers
Bobbie J. Rimel
Joyce F. Liu
Angeles Alvarez Secord
Erika Hamilton
Thomas J. Reid
Sharyn N. Lewin
Mary M. Mullen
K.A. Mills
Randy Anderson
Reshma A. Rangwala

TPS5605Background: The AXL receptor and its activating ligand, GAS6, are important drivers of metastasis and therapeutic resistance in human cancers. This signaling axis represents an attractive ta...

Keywords:

Internal medicine
Paclitaxel
Metastasis
Medicine
Placebo
Receptor
in patient
Oncology
GAS6
double blind
platinum resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations